Beam Therapeutics INC. (BEAM) — SEC Filings

Overview

Beam Therapeutics INC. (BEAM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: Beam Therapeutics Inc. reported a net loss of $112.7 million for the three months ended September 30, 2025, an increase from a net loss of $96.7 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $324.3 million from $286.4 million in 2024. Licen

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 3 bullish, 29 neutral, 2 mixed. The dominant filing sentiment for Beam Therapeutics INC. is neutral.

Filing Type Overview

Beam Therapeutics INC. (BEAM) has filed 11 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 12 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Recent Filings (34)

• 8-K Filing — 8-K · Dec 11, 2025
• Beam Therapeutics' Q3 Loss Widens Amid Soaring R&D Costs — 10-Q · Nov 4, 2025 Risk: high
  Beam Therapeutics Inc. reported a net loss of $112.7 million for the three months ended September 30, 2025, an increase from a net loss of $96.7 million in the
• Beam Therapeutics' Q2 Loss Widens to $130.6M Amid R&D Surge — 10-Q · Aug 5, 2025 Risk: high
  Beam Therapeutics Inc. reported a net loss of $130.6 million for the three months ended June 30, 2025, a significant increase from the $105.3 million net loss i
• Beam Therapeutics Reports Unregistered Equity Sale — 8-K · Jul 3, 2025 Risk: medium
  Beam Therapeutics Inc. announced on July 1, 2025, an unregistered sale of equity securities. The filing does not disclose the specific number of shares sold or
• Beam Therapeutics Files 8-K on Security Holder Vote — 8-K · Jun 6, 2025 Risk: medium
  Beam Therapeutics Inc. filed an 8-K on June 6, 2025, reporting on a matter submitted to a vote of its security holders on June 4, 2025. The filing does not disc
• Beam Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  Beam Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 26 Landsdowne Street, Cambridge, MA, reported on its financi
• Beam Therapeutics Executive Compensation Details — DEF 14A · Apr 18, 2025 Risk: low
  Beam Therapeutics Inc. filed its DEF 14A on April 18, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes i
• Pfizer to Acquire Beam Therapeutics for $13B — 8-K · Mar 10, 2025 Risk: medium
  Beam Therapeutics Inc. announced on March 10, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for approximately $13.0 billio
• Beam Therapeutics Files 2024 10-K — 10-K · Feb 25, 2025 Risk: medium
  Beam Therapeutics Inc. filed its 2024 10-K on February 25, 2025, reporting its fiscal year ending December 31, 2024. The company, focused on biological products
• Beam Therapeutics Files 8-K on Financials and Operations — 8-K · Jan 13, 2025 Risk: low
  Beam Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures re
• Beam Therapeutics Files 8-K — 8-K · Dec 9, 2024 Risk: low
  Beam Therapeutics Inc. filed an 8-K on December 9, 2024, reporting an event that occurred on December 7, 2024. The filing pertains to Regulation FD Disclosure,
• Beam Therapeutics Announces Board and Executive Changes — 8-K · Dec 6, 2024 Risk: medium
  Beam Therapeutics Inc. announced on December 5, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departur
• Beam Therapeutics Appoints New Director, Discloses Officer Compensation — 8-K · Dec 4, 2024 Risk: low
  Beam Therapeutics Inc. announced on December 2, 2024, a change in its board of directors. Dr. David R. Walt has been appointed as a new director, effective imme
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Nov 7, 2024
• Beam Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 5, 2024 Risk: medium
  Beam Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including details on its common
• SC 13G/A Filing — SC 13G/A · Oct 21, 2024
• SC 13G/A Filing — SC 13G/A · Oct 17, 2024
• Beam Therapeutics Q2 2024: Assets at $2.1B, Retained Earnings Negative — 10-Q · Aug 6, 2024 Risk: high
  Beam Therapeutics Inc. reported its Q2 2024 results, with total assets reaching $2.1 billion as of June 30, 2024. The company's retained earnings were negative
• Beam Therapeutics Adds Harvard Professor to Board — 8-K · Jul 15, 2024 Risk: low
  Beam Therapeutics Inc. announced on July 11, 2024, the election of Dr. Sarah E. Fortune to its Board of Directors. Dr. Fortune is a distinguished professor and
• Beam Therapeutics Files 8-K on Shareholder Votes — 8-K · Jun 10, 2024 Risk: low
  Beam Therapeutics Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of its security holders as of June 5, 2024. The filing details th
• Beam Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
  Beam Therapeutics Inc. (BEAM) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Beam Therapeutics reported financial results for the quarter ended Ma
• Beam Therapeutics Inc. files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · Apr 19, 2024 Risk: low
  Beam Therapeutics Inc. (BEAM) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. Beam Therapeutics Inc. will hold its 2024 Annual Meeting of Stoc
• Beam Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
  Beam Therapeutics Inc. (BEAM) filed a Annual Report (10-K) with the SEC on February 27, 2024. Beam Therapeutics Inc. filed its 2023 Form 10-K on February 27, 20
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Farallon Capital Partners Amends Beam Therapeutics Stake — SC 13G/A · Feb 12, 2024 Risk: low
  Farallon Capital Partners, L.P. filed an amended SC 13G/A on February 12, 2024, indicating a change in their ownership of Beam Therapeutics Inc. common stock as
• FMR LLC & Abigail Johnson Maintain 10.985% Stake in Beam Therapeutics — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its Chair and CEO, Abigail P. Johnson, have updated their ownership stake in Beam Therapeutics Inc. As of February 9, 2024
• Temasek Holdings Updates Passive Stake in Beam Therapeutics — SC 13G/A · Feb 6, 2024
  Temasek Holdings (Private) Ltd, a Singaporean investment company, filed an amended SC 13G/A on February 6, 2024, indicating a change in its ownership of Beam Th
• ARK Investment Management Boosts Stake in Beam Therapeutics — SC 13G/A · Jan 29, 2024
  ARK Investment Management LLC, led by Cathie Wood, filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in Beam Therapeutics Inc. As of Decem
• BlackRock Amends Beam Therapeutics Stake, Signals Continued Confidence — SC 13G/A · Jan 25, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership of Beam Therapeutics Inc. common stock as of December 31, 2023. This fili
• State Street Discloses Passive Stake in Beam Therapeutics — SC 13G · Jan 24, 2024
  State Street Corporation, a major financial institution, has filed an initial SC 13G on January 24, 2024, disclosing its ownership of common stock in Beam Thera
• Beam Therapeutics Files 8-K on Operations, Financial Condition — 8-K · Jan 8, 2024
  Beam Therapeutics Inc. filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and 'Other

Frequently Asked Questions